Butterfly Network (BFLY) Q1 2024: IQ3 Drives 22% Probe Volume Surge, Raising Growth Trajectory
IQ3’s rapid market adoption and robust probe demand delivered a record first quarter for Butterfly Network, prompting a guidance raise and extending the company’s cash runway. With new product launches, expanding enterprise traction, and a sharpened focus on non-dilutive growth levers, management signals a sustainable shift in business momentum. Investors should watch for international IQ3 rollout and home care monetization as next catalysts.
Summary
- IQ3 Launch Catalyzes Demand: New probe drove record Q1 volume and outperformed expectations.
- Cost Discipline Extends Runway: Efficiency gains halved cash burn and support future investment.
- Pipeline Depth Expands: Enterprise, medical education, and home care set up multi-year growth levers.
Business Overview
Butterfly Network develops and sells handheld, chip-based ultrasound devices and related software for medical, veterinary, and educational use. The company’s core revenue streams are product sales (probes and hardware), software subscriptions (enterprise and individual), and emerging service models (such as home care and AI partnerships). Major segments include U.S. healthcare providers, international distributors, medical schools, and growing veterinary and home care channels.
Performance Analysis
Butterfly delivered its highest first-quarter revenue in company history, powered by a 22% YoY increase in probe volume from the IQ3 launch and broad-based demand across channels. U.S. sales led with 19% growth, while international revenue rose 14% despite IQ3 not yet being available overseas. Product revenue advanced 28%, offsetting a slight decline in software and services, which now account for 36% of total revenue.
Gross margin remained stable at 58%, with product mix and higher software amortization balancing higher average selling prices. Adjusted EBITDA loss narrowed by $9.1M YoY, reflecting ongoing cost discipline—annualized cash burn now runs near $60M, with runway extended into 2026. The company’s largest-ever installed base and rising enterprise software penetration (now 42% of ARR) signal a shift toward higher-value, recurring revenue streams.
- IQ3 Penetration Accelerates: Over 1200 IQ3 units sold in less than half a quarter, with roughly half to new customers and half as upgrades, validating product-market fit.
- Enterprise and Education Momentum: Notable wins in health systems and medical schools, including one-to-one deployments and upsells, reinforce Butterfly’s value proposition.
- Software Transition Underway: Temporary dip in individual subscriptions offset by strong enterprise ARR growth and new probe-driven software activation pipeline.
Cost structure improvements and higher ASPs are enabling Butterfly to invest in growth while maintaining financial flexibility. The company’s multi-segment demand and deepening enterprise adoption underpin management’s confidence in raising full-year guidance.
Executive Commentary
"Our IQ3 launch proved everything we were hoping for and marks a major shift in competitiveness for the health system market. With our building momentum from recent product launches along with a robust line of new products and services coming, we feel confident we will be able to sustain this growth for the foreseeable future."
Joseph DeVivo, Chairman and Chief Executive Officer
"As we have previously discussed, over the last 18 months, we have taken over $170 million of cost out of the business and have reduced our annual cash burn to approximately $60 million. Based on this, we estimate that our cash balance conservatively provides us with a runway into 2026, and we have a plan to extend it further."
Heather Goetz, Chief Financial and Operations Officer
Strategic Positioning
1. IQ3 Launch Redefines Product Competitiveness
IQ3, Butterfly’s next-generation probe, is now positioned as the market’s “best handheld in image quality, capabilities, and cost,” according to management. The device addresses prior specialty gaps—especially in cardiology—while maintaining a price point far below multi-probe competitors. Early demand was split evenly between new users and upgrades, and IQ3 is expected to drive further share gains as it rolls out internationally.
2. Multi-Segment Expansion and Enterprise Penetration
Butterfly is deepening its presence in health systems, medical education, and veterinary markets. Recent wins include major one-to-one deployments (e.g., University of Rochester), expanded medical school partnerships, and new veterinary alliances with Chewy, Petco, and PetSmart. These channels are cited as key growth drivers, with significant pipeline visibility into 2025.
3. Software and AI Ecosystem Development
Enterprise software and AI partnerships are becoming more central to Butterfly’s business model. The company’s Butterfly Garden and Powered by Butterfly programs are generating recurring revenue and building a platform for third-party AI app development. Notably, enterprise software now comprises 42% of ARR, and new probe sales are expected to drive future software adoption.
4. Home Care and Services Monetization
Butterfly is transitioning toward service-based and outcomes-driven revenue models in home care, targeting congestive heart failure management and bladder volume monitoring. Management envisions service fees and risk-sharing contracts, rather than device sales, as the core of this channel—potentially unlocking a large new addressable market starting in 2025.
5. Regulatory and Capital Flexibility
Butterfly’s chip-based technology positions it favorably for upcoming EU regulatory changes, as the company expects possible bans on legacy lead-based handhelds. Additionally, management is pursuing non-dilutive capital sources, such as grants and technology licensing, to extend its runway and accelerate the path to profitability without shareholder dilution.
Key Considerations
Butterfly’s Q1 marked a turning point, with operational execution, product innovation, and financial discipline converging to set up a multi-year growth trajectory. Key factors to monitor going forward:
- International IQ3 Rollout Timing: Approval and launch in Canada and Europe will test the global demand thesis and drive incremental growth in coming quarters.
- Software Revenue Mix Recovery: Enterprise growth is strong, but a rebound in individual subscriptions and overall software mix will be crucial for margin expansion.
- Home Care Monetization Path: Success in establishing service-based, risk-sharing contracts will determine the scale and profitability of this emerging channel.
- Non-Dilutive Financing Execution: Progress on licensing, grants, and Powered by Butterfly partnerships will be key to extending the cash runway and protecting shareholder value.
- Regulatory Outcomes in Europe: The pending RoHS directive review could create a competitive moat if legacy devices are restricted, but timing and process risks remain.
Risks
Butterfly faces execution risk as it scales new product launches and transitions to higher-value service and software revenue streams. Regulatory timing in Europe and the company’s NYSE compliance status introduce uncertainty, though management frames these as manageable. Competitive pressure from established ultrasound vendors and the need to sustain enterprise and education pipeline momentum are ongoing challenges. Any delays in international IQ3 rollout or slower-than-expected adoption in home care could temper near-term upside.
Forward Outlook
For Q2 2024, Butterfly guided to:
- Approximately $20 million in revenue (about 10% YoY growth, facing a tough comp from prior-year medical school deals)
- Adjusted EBITDA loss of $12 to $13 million
For full-year 2024, management raised guidance:
- Revenue of $75 to $80 million (15% to 20% YoY growth)
- Adjusted EBITDA loss of $55 to $50 million
Management highlighted several factors that will shape the year:
- Continued IQ3 adoption and international launch cadence
- Ongoing cost discipline and pursuit of non-dilutive capital sources
Takeaways
Butterfly’s Q1 results confirm a shift from stabilization to growth, with IQ3 demand, operational execution, and expanding enterprise traction driving a raised outlook.
- Record Probe Volume: IQ3’s rapid uptake validates Butterfly’s product strategy and points to sustained competitive advantage in handheld imaging.
- Business Model Diversification: Software, AI, and service initiatives are building recurring revenue streams and opening new market opportunities beyond hardware sales.
- Future Growth Catalysts: Watch for international IQ3 launches, home care monetization, and regulatory tailwinds in Europe as key levers for upside in 2024 and beyond.
Conclusion
Butterfly Network’s Q1 marked a decisive return to growth, with IQ3 driving record sales and operational discipline extending its financial runway. The company’s multi-pronged strategy—anchored in product innovation, enterprise expansion, and new service models—positions it for sustainable top-line growth and improved margin trajectory as execution continues.
Industry Read-Through
Butterfly’s Q1 performance and strategic pivots underscore accelerating disruption in point-of-care imaging, with handheld ultrasound adoption moving from niche to mainstream across multiple clinical settings. The rise of chip-based devices and integrated AI platforms signals mounting pressure on legacy cart-based vendors to innovate or risk share loss. Regulatory shifts in Europe could reshape competitive dynamics, favoring digital-first players. For the broader medtech sector, Butterfly’s blend of capital discipline, recurring revenue focus, and platform partnerships offers a playbook for navigating today’s funding and adoption environment. Investors should monitor how other device makers adapt their go-to-market, software, and international strategies in response.